228 related articles for article (PubMed ID: 20195281)
21. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire.
Nastke MD; Herrgen L; Walter S; Wernet D; Rammensee HG; Stevanović S
Cell Mol Life Sci; 2005 Jan; 62(1):77-86. PubMed ID: 15619009
[TBL] [Abstract][Full Text] [Related]
22. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy.
Trivedi D; Williams RY; O'Reilly RJ; Koehne G
Blood; 2005 Apr; 105(7):2793-801. PubMed ID: 15514011
[TBL] [Abstract][Full Text] [Related]
23. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
[TBL] [Abstract][Full Text] [Related]
24. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients.
Lilleri D; Zelini P; Fornara C; Comolli G; Gerna G
Am J Transplant; 2007 Aug; 7(8):1997-2005. PubMed ID: 17617865
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein.
Carlsson B; Hou M; Giandomenico V; Nilsson B; Totterman TH; Essand M
J Infect Dis; 2005 Dec; 192(11):1912-20. PubMed ID: 16267762
[TBL] [Abstract][Full Text] [Related]
26. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
[TBL] [Abstract][Full Text] [Related]
27. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus.
Frankenberg N; Pepperl-Klindworth S; Meyer RG; Plachter B
Virology; 2002 Apr; 295(2):208-16. PubMed ID: 12033779
[TBL] [Abstract][Full Text] [Related]
28. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.
Solache A; Morgan CL; Dodi AI; Morte C; Scott I; Baboonian C; Zal B; Goldman J; Grundy JE; Madrigal JA
J Immunol; 1999 Nov; 163(10):5512-8. PubMed ID: 10553078
[TBL] [Abstract][Full Text] [Related]
29. Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2.
Braendstrup P; Mortensen BK; Justesen S; Osterby T; Rasmussen M; Hansen AM; Christiansen CB; Hansen MB; Nielsen M; Vindeløv L; Buus S; Stryhn A
PLoS One; 2014; 9(4):e94892. PubMed ID: 24760079
[TBL] [Abstract][Full Text] [Related]
30. Progress made towards the development of a CMV peptide vaccine.
Paston SJ; Dodi IA; Madrigal JA
Hum Immunol; 2004 May; 65(5):544-9. PubMed ID: 15172455
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS; Mackinnon S
Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
[TBL] [Abstract][Full Text] [Related]
32. Cross-presentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells.
Arrode G; Boccaccio C; Abastado JP; Davrinche C
J Virol; 2002 Jan; 76(1):142-50. PubMed ID: 11739680
[TBL] [Abstract][Full Text] [Related]
33. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
[TBL] [Abstract][Full Text] [Related]
34. Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition.
Besold K; Wills M; Plachter B
Virology; 2009 Aug; 391(1):5-19. PubMed ID: 19570562
[TBL] [Abstract][Full Text] [Related]
35. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles.
Lacey SF; Villacres MC; La Rosa C; Wang Z; Longmate J; Martinez J; Brewer JC; Mekhoubad S; Maas R; Leedom JM; Forman SJ; Zaia JA; Diamond DJ
Hum Immunol; 2003 Apr; 64(4):440-52. PubMed ID: 12651070
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
[TBL] [Abstract][Full Text] [Related]
37. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
Britten CM; Meyer RG; Graf C; Huber C; Wölfel T
J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199
[TBL] [Abstract][Full Text] [Related]
38. Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes.
Lim JB; Kim HO; Jeong SH; Ha JE; Jang S; Lee SG; Lee K; Stroncek D
J Transl Med; 2009 Aug; 7():72. PubMed ID: 19698161
[TBL] [Abstract][Full Text] [Related]
39. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants.
Gibson L; Dooley S; Trzmielina S; Somasundaran M; Fisher D; Revello MG; Luzuriaga K
J Infect Dis; 2007 Jun; 195(12):1789-98. PubMed ID: 17492595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
